Clinical and laboratory characteristics of hyperandrogenism in women on the background of hyperprolactinemia

Abstract

Aim. To determine the clinical and diagnostic features of hyperandrogenism on the background of hyperprolactinemia.

Methods. 68 women with hyperandrogenism on the background of hyperprolactinemia were examined. The study included defining features of menstrual function, assessment of hair growth according to Ferriman-Gallwey score, determining the frequency of past somatic and gynecological diseases, anthropometric indicators before and after the combination pathogenetic therapy, study of hormone levels.

Results. In women with hyperandrogenism, rate of isolated form of hyperprolactinemia was 39.7%, combined form - 60.3%. The causes of the «pure» form of hyperandrogenism in 51.85% is a idiopathic form of hyperprolactinemia, in 25.9% - the intracellular pituitary microadenoma, in 14.81% - drug-induced form of hyperprolactinemia, in 4.7% - «empty» sella syndrome. In combined form of hyperprolactinemia in 29.3% of patients, polycystic ovary syndrome and insulin resistance is determined, in 17% - polycystic ovary syndrome without insulin resistance, in 17% - obesity, in 14.63% - primary hypothyroidism. Patients underwent pathogenetic therapy, which was chosen individually depending on the type of hyperprolactinemia, and the presence of underlying diseases.

Conclusion. In combined form of hyperprolactinemia the most frequent types of comorbidity are polycystic ovary syndrome and insulin resistance, the most common form of «pure» hyperprolactinemia is idiopathic form; pathogenetic therapy significantly reduces prolactin and androgens values, improves basic anthropometric indicators of patients.

Keywords

hyperandrogenism / hyperprolactinemia / infertility

References

[1] Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М., Тверь: Триада. 2004; 304 с.

[2] Забаровская З.В., Кушнир Л.С., Билодид И.К. Первичная заболеваемость гиперпролактинемией у женщин репродуктивного возраста. Эндокринология. ARS MEDİCA. 2012; 70 (15): 110-115.

[3] Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study un Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.). 2010; (72): 377-382. http://dx.doi.org/10.1111/j.1365-2265.2009.03667.x

[4] Kars M., Souverein P.C., Herings R.M., Romijn J.A. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. Am. J. Clin. Endocrinol. Metab. 2009; (94): 2729-2734. http://dx.doi.org/10.1210/jc.2009-0177

[5] McKenna T.J. Should macroprolactin be measured in all hyperprolactinaemic sera? Am. J. Clin. Endocrinol. 2009; (71): 466-469. http://dx.doi.org/10.1111/j.1365-2265.2009.03577.x

[6] Melmed S., Kleinberg D. Anterior pituitary. 11th ed. Philadelphia: Saunders Elsevier. 2008; 185-261.

[7] Melmed S., Casanueva F.F., Hoffman A.R. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011; (96): 273-288. http://dx.doi.org/10.1210/jc.2010-1692

[8] Molitch M.E. Prolactinomas and pregnancy. Am. Clin. Endocrin. 2010; (73): 147-148.

[9] Ono M., Miki N., Amano K. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Am. J. Clin. Endocrin. Metab. 2010; (95): 2672-2679. http://dx.doi.org/10.1210/jc.2009-2605

[10] Swiglo B.A., Murad M.H., Schünemann H.J. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. Am. J. Clin. Endocrinol. Metab. 2008; (93): 666-673. http://dx.doi.org/10.1210/jc.2007-1907

RIGHTS & PERMISSIONS

Akhundova N.E.